451 related articles for article (PubMed ID: 21620416)
1. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial.
Smolders J; Hupperts R; Barkhof F; Grimaldi LM; Holmoy T; Killestein J; Rieckmann P; Schluep M; Vieth R; Hostalek U; Ghazi-Visser L; Beelke M;
J Neurol Sci; 2011 Dec; 311(1-2):44-9. PubMed ID: 21620416
[TBL] [Abstract][Full Text] [Related]
2. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of daily high-dose vitamin D
Hupperts R; Smolders J; Vieth R; Holmøy T; Marhardt K; Schluep M; Killestein J; Barkhof F; Beelke M; Grimaldi LME;
Neurology; 2019 Nov; 93(20):e1906-e1916. PubMed ID: 31594857
[TBL] [Abstract][Full Text] [Related]
4. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr KM; Søgaard LV; Olsen IC; Sandberg-Wollheim M
Lancet Neurol; 2009 Jun; 8(6):519-29. PubMed ID: 19409854
[TBL] [Abstract][Full Text] [Related]
5. Immune regulatory effects of high dose vitamin D
Muris AH; Smolders J; Rolf L; Thewissen M; Hupperts R; Damoiseaux J;
J Neuroimmunol; 2016 Nov; 300():47-56. PubMed ID: 27806875
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial.
Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ
Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030
[TBL] [Abstract][Full Text] [Related]
7. A randomized trial of high-dose vitamin D2 in relapsing-remitting multiple sclerosis.
Stein MS; Liu Y; Gray OM; Baker JE; Kolbe SC; Ditchfield MR; Egan GF; Mitchell PJ; Harrison LC; Butzkueven H; Kilpatrick TJ
Neurology; 2011 Oct; 77(17):1611-8. PubMed ID: 22025459
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.
Sorensen PS; Lycke J; Erälinna JP; Edland A; Wu X; Frederiksen JL; Oturai A; Malmeström C; Stenager E; Sellebjerg F; Sondergaard HB;
Lancet Neurol; 2011 Aug; 10(8):691-701. PubMed ID: 21742556
[TBL] [Abstract][Full Text] [Related]
9. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D-mediated immune regulation in multiple sclerosis.
Correale J; Ysrraelit MC; Gaitán MI
J Neurol Sci; 2011 Dec; 311(1-2):23-31. PubMed ID: 21723567
[TBL] [Abstract][Full Text] [Related]
11. Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis.
Røsjø E; Steffensen LH; Jørgensen L; Lindstrøm JC; Šaltytė Benth J; Michelsen AE; Aukrust P; Ueland T; Kampman MT; Torkildsen Ø; Holmøy T
J Neurol; 2015 Dec; 262(12):2713-21. PubMed ID: 26429571
[TBL] [Abstract][Full Text] [Related]
12. A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon β-1b in patients with multiple sclerosis.
Soilu-Hänninen M; Aivo J; Lindström BM; Elovaara I; Sumelahti ML; Färkkilä M; Tienari P; Atula S; Sarasoja T; Herrala L; Keskinarkaus I; Kruger J; Kallio T; Rocca MA; Filippi M
J Neurol Neurosurg Psychiatry; 2012 May; 83(5):565-71. PubMed ID: 22362918
[TBL] [Abstract][Full Text] [Related]
13. Prospective assessment of changing from placebo to IFN beta-1a in relapsing MS: the PRISMS study.
Oger J; Francis G; Chang P;
J Neurol Sci; 2005 Oct; 237(1-2):45-52. PubMed ID: 16026803
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy.
Lanzillo R; Orefice G; Quarantelli M; Rinaldi C; Prinster A; Ventrella G; Spitaleri D; Lus G; Vacca G; Carotenuto B; Salvatore E; Brunetti A; Tedeschi G; Brescia Morra V
Mult Scler; 2010 Apr; 16(4):450-4. PubMed ID: 20150398
[TBL] [Abstract][Full Text] [Related]
15. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
[TBL] [Abstract][Full Text] [Related]
16. ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial.
Torkildsen O; Wergeland S; Bakke S; Beiske AG; Bjerve KS; Hovdal H; Midgard R; Lilleås F; Pedersen T; Bjørnarå B; Dalene F; Kleveland G; Schepel J; Olsen IC; Myhr KM
Arch Neurol; 2012 Aug; 69(8):1044-51. PubMed ID: 22507886
[TBL] [Abstract][Full Text] [Related]
17. Management of worsening multiple sclerosis with mitoxantrone: a review.
Fox EJ
Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
[TBL] [Abstract][Full Text] [Related]
18. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
[TBL] [Abstract][Full Text] [Related]
19. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Birnbaum G; Cree B; Altafullah I; Zinser M; Reder AT
Neurology; 2008 Oct; 71(18):1390-5. PubMed ID: 18525027
[TBL] [Abstract][Full Text] [Related]
20. The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial: study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis.
Bhargava P; Cassard S; Steele SU; Azevedo C; Pelletier D; Sugar EA; Waubant E; Mowry EM
Contemp Clin Trials; 2014 Nov; 39(2):288-93. PubMed ID: 25311447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
